With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Long Covid remains poorly understood and follow-up studies play an integral role in establishing an epidemiological and ...

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

In previous studies of MSCs for ischaemic heart failure, higher doses caused a decrease in myocardial scarring. Credit: MMD Creative / Shutterstock. An independent Data Safety Monitoring Board (DSMB) ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.

Neuren has confirmed the primary goals for its double-blind, single Phase III pivotal trial of NNZ-2591 in treating PMS for ...

A study by Larsen and colleagues has exemplified the role that HCs have in heightening depression risk in this group.

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced solid tumours.